263 results about "Aids diagnostics" patented technology

The invention relates to a chest pain classification method and system based on multi-modal data fusion and a deep learning model, and belongs to the technical field of intelligent medical auxiliary diagnosis. The method comprises the following steps: firstly, carrying out heart region segmentation and pathological feature enhancement preprocessing on a chest radiograph image, extracting anatomical features by adopting a multi-scale visual model which is optimized and improved aiming at the chest radiograph, meanwhile, carrying out multi-lead time sequence calibration and ST-segment waveform marking on an electrocardiogram signal, and capturing electrophysiological time sequence features through a multi-scale one-dimensional convolutional network; then, a dynamic gating hybrid expert system is constructed, an anatomy expert, an electrophysiology expert, a multi-modal association expert and a critical value expert process specific modal features respectively, and a gating network dynamically calculates expert weights based on real-time vital signs and pathological features; according to the method, by integrating multi-modal data and combining a deep learning technology, rapid and accurate chest pain classification support and report generation can be provided for clinicians, and the method has a wide application prospect.

The invention belongs to the technical field of biological medicines, and particularly relates to application of a macrophage Angulin-1 gene and / or an Angulin-1 protein in preparation of medicines and diagnostic products for preventing and / or treating atherosclerosis and related diseases. Research finds that plaque and necrotic core areas of an atherosclerosis animal model are remarkably increased due to macrophage Angulin-1 gene knockout, and disease development is promoted; and the recovery of the expression level of Angulin-1 significantly inhibits the development of lesion. Cell experiments show that Angulin-1 reduces intake of oxidized low-density lipoprotein by down-regulating expression of macrophage LOX-1, so that formation of foam cells is inhibited. Therefore, the macrophage Angulin-1 can be used as an atherosclerosis drug target, a gene therapy target gene and an auxiliary diagnosis marker, and a new theoretical basis and an intervention strategy are provided for prevention and treatment of the disease.

The invention provides an antigen epitope peptide related to connexin and application of the antigen epitope peptide. The connexin antigen epitope peptide disclosed by the invention is selected from (1) a polypeptide with an amino acid sequence as shown in SEQ ID NO: 14; and (2) a polypeptide which is derived from (1) by substituting, deleting or adding 1-2 amino acids in the amino acid sequence of SEQ ID NO: 14 and retains the binding capacity with a connexin antibody. According to the present invention, the new connexin antigenic peptide fragment sequence is identified for the first time, such that the existing autoantigen epitope map is expanded, and more importantly, the molecular basis is provided for the development of the clinical detection method with high diagnosis sensitivity and high specificity, such that the pathological mechanism of MG can be further improved, and the application prospect is broad. And new auxiliary diagnosis means and treatment targets are provided for antibody negative MG patients.

The invention discloses an abnormal heart beat detection method and system based on a magnetic cardiogram, and relates to the technical field of medical data processing, and the method comprises the steps: carrying out the preprocessing of original magnetic cardiogram data; magnetic cardiogram features are extracted based on discrete wavelet transform, model parameters are adjusted, and an abnormal heart beat detection model is obtained; and judging whether abnormal heart beat exists or not and the position. According to the method, the problem that the magnetocardiogram data lacks a large number of heart beat level labeling samples is effectively solved, dependence on labeling data is reduced, automatic, efficient and accurate detection of abnormal heart beats is achieved, the good clinical application prospect is achieved, and powerful support can be provided for early screening, auxiliary diagnosis and risk assessment of arrhythmia.

The invention provides application of a substance for detecting the ratio of lymphocyte subgroups in preparation of a reagent or a kit for diagnosis or auxiliary diagnosis of Graves disease, and belongs to the technical field of preparation of disease diagnosis reagents. A research shows that compared with a healthy sample, the proportion of B cells in a lymphocyte subpopulation of a to-be-detected sample is remarkably increased, the proportion of NK cells is remarkably reduced, the proportion of activated T cells is remarkably reduced, the proportion of memory T cells is remarkably reduced, the proportion of CD4 + memory T cells is remarkably reduced, the proportion of Th1 cells is remarkably reduced, and the proportion of Tc1 cells is remarkably reduced, so that the to-be-detected sample is a GD patient; the substance for detecting the ratio of lymphocyte subgroups is high in sensitivity and specificity when being used for diagnosis or auxiliary diagnosis of Graves disease.

The invention discloses an auxiliary diagnosis system for renal transplantation rejection and typing thereof based on a peripheral blood immune cell map. Comprising a peripheral blood single cell acquisition unit, a mass spectrum flow cytometry unit, an original data preprocessing unit, a data conversion and normalization processing unit, a peripheral blood immune cell grouping acquisition unit, a peripheral blood immune cell map construction unit, a feature vector acquisition unit, a rejection prediction unit and a rejection typing prediction unit. According to the invention, a kidney transplantation two-stage diagnosis architecture is created for the first time; rejection detection and typing identification are realized through classification of an independently trained random forest binary classifier, and different TCMR / ABMR immune mechanisms are accurately matched; the traditional biopsy limitation is broken through, an auxiliary diagnosis scheme with high precision, low damage, moderate cost and typing identification capability is provided for the kidney transplantation rejection, and the method has important significance on timely discovery of the rejection of a kidney transplantation patient and improvement of prognosis.

The invention relates to the field of disease prediction, in particular to a cognitive impairment prediction system based on synchronously acquired electroencephalogram-stomach electrical signals, comprising: a data acquisition module for acquiring data including electroencephalogram data and stomach and intestine electrical data; the first analysis module is used for obtaining an average electrode inconsistency index of the first channel and the second channel based on a first model according to the time sequence data; and the prediction module is used for comparing the average electrode inconsistency index of the subject with a preset evaluation threshold value so as to predict a cognitive impairment patient. The system provided by the invention can more accurately and efficiently distinguish patients with mild cognitive impairment from healthy people, and can be used as an auxiliary diagnosis tool to be applied to primary screening of mild cognitive impairment on relatively large people (such as communities and physical examination centers).

The invention discloses a marker for early colorectal neoplastic lesion diagnosis and application, and belongs to the technical field of biological medicine. Aiming at the problems of low colonoscopy coincidence rate of colorectal cancer patients at present and limited sensitivity and specificity of existing biomarker diagnosis, LncRNA sequencing research is combined with expanded sample verification to obtain high-specificity and high-sensitivity LncRNA which is highly related to colorectal neoplastic lesions (including adenoma and colorectal cancer), the LncRNA is specifically LOC401585, and the LncRNA has the advantages of high specificity, high sensitivity, high specificity and high sensitivity and can be used for detecting colorectal neoplastic lesions (including adenoma and colorectal cancer). The diagnosis efficacy AUC of the LOC401585 on the adenoma and the colorectal cancer is 0.952 and 0.876 respectively. Therefore, the blood LOC401585 marker can be used for auxiliary diagnosis of colorectal neoplastic lesions, and provides data support for finding novel small molecule drugs with potential treatment value.

Provided is an application of a circular RNA in the preparation of a cerebral stroke diagnosis product, belonging to the field of circular RNA medical treatments. Provided is a kit, comprising a reagent and / or test paper and / or gene chip for detecting a circular RNA-circ-Magi1. The nucleotide sequence of the circular RNA-circ-Magi1 is as shown in SEQ ID NO: 1 or SEQ ID NO: 4. Further provided is the application of a detection system for the diagnosis, assisted diagnosis or prognosis evaluation of cerebral stroke, and a detection reagent of the circular RNA-circ-Magi1 in the preparation of a kit, test paper, chip or high-throughput sequencing platform for the diagnosis, assisted diagnosis or prognosis evaluation of cerebral stroke.

The invention relates to the technical field of biological medicine, and provides application of TRIM69 in preparation of a kit for auxiliary diagnosis of systemic lupus erythematosus. The kit assists in diagnosing systemic lupus erythematosus by detecting the TRIM69 level. Through the mRNA expression quantity of the TRIM69 and the expression quantity and / or concentration of the protein, the auxiliary diagnosis of the systemic lupus erythematosus is realized, and the TRIM69 as a biomarker has important values in the aspects of auxiliary diagnosis, disease activity monitoring, prognosis evaluation, diagnosis efficiency improvement and the like. Not only can a doctor be helped to recognize a high-risk patient earlier, but also a basis can be provided for individualized treatment, so that the long-term prognosis of the systemic lupus erythematosus patient is improved.

The invention belongs to the technical field of biological medicine, and particularly relates to application of macrophage LSR gene and / or LSR protein in preparation of drugs and diagnostic products for preventing and / or treating diabetic nephropathy. Research finds that the LSR deletion of macrophages aggravates renal injury by promoting inflammatory response of diabetic nephropathy and increasing lipid renal toxicity; on the contrary, after the LSR expression of the macrophages is recovered, the inflammatory response and lipid droplet deposition of the kidney of the diabetic nephropathy mouse can be effectively reduced, and meanwhile, the kidney injury is improved. Cell experiments show that LSR deletion of macrophages can activate a YAP signal channel to increase secretion of inflammatory factors and reduce low-density lipoprotein uptake at the same time. Therefore, the macrophage LSR can be used as a diabetic nephropathy drug target, a gene therapy target gene and an auxiliary diagnosis marker, and a new theoretical basis and an intervention strategy are provided for prevention and treatment of the disease.

The invention discloses a newborn rare disease clinical feature auxiliary diagnosis system based on deep learning, relates to the technical field of medical diagnosis, and aims to solve the problem of multi-dimensional high-dimensional data feature fusion, break through the generalization ability limitation of a traditional diagnosis model, accurately capture a hidden feature combination and improve the diagnosis accuracy. The neonatal rare disease diagnosis system comprises a medical database module used for storing medical training samples and medical data of a patient to be diagnosed; the deep learning system is used for carrying out feature extraction, coding, matching and diagnosis on the medical data; the diagnosis result visualization tool comprises a visualization tool and a textualization tool. According to the method, multi-dimensional high-dimensional data are fused through the feature embedding module, the generalization limitation of a traditional diagnosis model is broken through, and hidden feature combinations are accurately captured; the training feature coding module reduces the over-fitting risk, and for complex cases of methylmalonic acidmia, the diagnosis accuracy is greatly improved compared with a traditional method.

The invention discloses an oral microbial marker composition and application thereof in preparation of a kit for diagnosing high altitude headache, and particularly relates to the technical field of molecular biotechnology detection. A diagnosis model constructed on the basis of oral flora finds that the provided oral flora marker combination can specifically recognize patients with high altitude headache from plateau healthy people. The kit is used for predicting the high-altitude headache illness condition and clinical auxiliary diagnosis, is good in detection specificity and high in sensitivity, can indicate the condition of the high-altitude headache tissue microbial flora, and can guide the clinical diagnosis mode of the high-altitude headache and the adjustment of medication so as to reduce the probability of misdiagnosis and missed diagnosis in clinical diagnosis. The oral flora marker has important application in the aspects of screening and diagnosis of high altitude headache and the like, so that health damage and life risks caused by diseases are reduced.

The invention provides a sleep apnea and hypopnea intelligent monitoring and auxiliary diagnosis system and method based on a flexible sensor, and belongs to the technical field of sensors and respiration monitoring equipment. The system comprises a resistive flexible strain sensor, a wireless data acquisition card and a portable data processing terminal, a resistance-type flexible strain sensor is adhered to the skin surface of a main muscle group and an auxiliary muscle group related to human respiration, resistance signals related to the respiration frequency and amplitude are obtained, respiration data of a patient are collected in real time, and further, self-adaptive amplitude alarm upper and lower limits are constructed through statistical modeling of the individual resting respiration amplitude, so that the respiration alarm accuracy is improved. Therefore, the individual adaptability and robustness of the respiration detection system are improved.

This invention discloses a combination of biomarkers for the auxiliary diagnosis of chronic pain comorbid with depression and its application, belonging to the fields of in vitro diagnostics (IVD) and clinical testing technology. The biomarker combination includes interleukin-6 (IL-6), interleukin-12 (IL-12), and the concentration ratio of kynurenic acid to 3-hydroxykynurenine (KYNA / 3-HK). This invention also discloses the application of this biomarker combination in an in vitro diagnostic kit for chronic pain comorbid with depression. Experimental results show that the diagnostic efficacy of this biomarker combination (AUC=0.871) is significantly better than that of a single biomarker, effectively distinguishing patients with chronic pain comorbid with depression from those without chronic pain, providing an objective auxiliary diagnostic tool for clinical practice.

The invention provides an ischemic stroke auxiliary diagnosis system based on a peripheral blood T cell single cell transcriptome and application thereof, and the auxiliary diagnosis system comprises a peripheral blood mononuclear cell acquisition module, a single cell RNA sequencing module, a data processing module, a data analysis module and a result discrimination module. With a coding gene of a protein molecule significantly related to the occurrence of ischemic stroke as a target gene, a data processing module obtains the expression level of the target gene in each T cell; the data analysis module obtains a risk score of each T cell of the subject by using a built-in single cell risk scoring model, and weights the risk scores of all the T cells through distributed perception identification to obtain an individual risk score of the subject; and the result judgment module is used for classifying the subjects into ischemic stroke negative and ischemic stroke positive according to the individualized risk scores of the subjects. The auxiliary diagnosis system disclosed by the invention is high in ischemic stroke discrimination capability, and high in sensitivity and specificity.

The invention provides application of a CHD1L detection reagent in preparation of a drug-resistant breast cancer screening kit, and belongs to the field of biological medicine. Researches find that when the CHD1L gene expression level in cancer tissues of a breast cancer patient is high, the breast cancer patient is prone to drug resistance to paclitaxel drugs, and the treatment effect of the paclitaxel drugs is poor. The reagent for detecting the CHD1L gene expression level is used for preparing the drug-resistant breast cancer screening kit, can be used for auxiliary diagnosis of clinical breast cancer types, provides an effective basis for related treatment measures or decisions of patients, and has a good clinical application prospect.

This invention discloses a lncRNA biomarker associated with AML, characterized in that the lncRNA biomarker is lncRNA FOXN3-AS1, and the nucleotide sequence of lncRNA FOXN3-AS1 is shown in SEQ ID NO: 1. This invention also discloses the application of a detection kit and method in the diagnosis and prognosis of AML. The lncRNA FOXN3-AS1 of this invention, as an auxiliary diagnostic biomarker for clinical detection of AML, has the advantages of simple operation, low cost, and accurate detection, making it suitable for clinical screening. The biomarker provided by this invention can be applied to the preparation of early AML assessment products, which is beneficial for further elucidating the pathogenesis of AML and helps in the discovery of novel small molecule drug targets with potential therapeutic value.

The embodiment of the application discloses an echocardiogram auxiliary report generation method, system, device and storage medium, and relates to the technical field of medical treatment. The echocardiogram auxiliary report generation method first aligns the input echocardiogram video through automatic registration, then identifies the starting time of each cardiac cycle in the echocardiogram video, generates the echocardiogram video frame of each cardiac cycle based on a preset frame number, divides the heart structure in the echocardiogram video frame into N target images of target regions by using a medical image segmentation model, obtains a structure parameter, inputs the structure parameter into an echocardiogram knowledge graph to automatically generate an auxiliary report, including an auxiliary diagnosis report and / or an auxiliary interpretation report. Therefore, doctors do not need to manually measure and fill in related clinical parameters or diagnosis opinions, and the health status of patients can be understood, and the working pressure of doctors is effectively reduced.

This invention discloses a multimodal imaging and multidimensional index evaluation software and hardware system for scars, involving an infrared, RGB, and stereoscopic three-modal imaging hardware system, and an intelligent calculation and monitoring software system for more than twenty scar evaluation indicators. The intelligent evaluation system for scars includes indicators such as perimeter, length, width, thickness, area, volume, color, roughness, consistency, elasticity, blood flow density, risk of continued scar growth, and color difference. This forms an objective, multidimensional, precise, and intelligent evaluation system for the scar diagnosis and treatment process, thereby assisting in diagnosis and treatment, as well as monitoring and tracking the entire life cycle of scars. This contributes to the visualization, objectification, and accuracy of the scar diagnosis and treatment process, providing doctors and patients with comprehensive diagnostic and treatment evidence and enabling tracking and tracing.

The invention discloses a specific antibody for detecting cathepsin S, a kit and application. The specific antibody for detecting cathepsin S is prepared by coupling a cathepsin S specific antigen epitope peptide with a carrier protein and then immunizing an animal, and the amino acid sequence of the antigen epitope peptide is at least one of a sequence shown as SEQ ID NO.1 and a sequence shown as SEQ ID NO.2. The specific antibody for detecting cathepsin S can specifically detect cathepsin S, and has the advantages of high sensitivity, good specificity, good repeatability and the like; when being used for auxiliary diagnosis or curative effect evaluation of the chronic obstructive pulmonary disease, the marker has good diagnosis sensitivity, specificity and repeatability, meets clinical application requirements, provides a more accurate and reliable objective index for auxiliary diagnosis, illness monitoring and prognosis evaluation of the chronic obstructive pulmonary disease, and is worthy of popularization and application. The method has important significance and clinical application value for diagnosis and treatment of chronic obstructive pulmonary diseases.

The invention is applicable to the technical field of clinical examination and auxiliary diagnosis, and provides an extreme behavior risk auxiliary diagnosis biomarker combination, a kit and a detection method, the biomarker combination is composed of IL-4, IL-12 and IFN gamma, and the extreme behavior risk can be objectively identified by detecting the expression level of the combination in peripheral blood of a subject. The matched kit comprises specific antibodies aiming at the three markers, a standard substance, a buffer solution and other reagents, and according to the standardized detection method, through peripheral blood sample treatment, incubation, fluorescent staining, flow detection and result analysis, precise evaluation is achieved in combination with a clear judgment threshold value. According to the method, the defect that suicide risk assessment depends on a subjective scale and doctor experience in the prior art is overcome, the operation is convenient, the result is objective, the combined detection AUC of the suicide risk assessment, the subjective scale and the doctor experience can reach 0.726, a reliable extreme behavior risk auxiliary diagnosis means is provided for clinic, and the method is particularly suitable for risk identification of depression patients and has important clinical application value and conversion prospect.

This invention discloses a device and its application for distinguishing between pneumonia and tuberculosis in children. By detecting S100A8 / A9 and determining the corresponding diagnostic threshold, this invention achieves rapid, sensitive, and specific differentiation between children with tuberculosis and normal children, as well as children with pneumonia caused by other pathogens. It provides a reliable basis for clinical auxiliary diagnosis, improves diagnostic efficiency and accuracy, avoids misdiagnosis and missed diagnosis, and can thus guide rational clinical treatment and improve patient prognosis.

The invention relates to the technical field of image detection, and discloses a thyroid postoperative hematoma early warning method, system and terminal based on multi-modal imaging, and the method comprises the steps: obtaining a thyroid postoperative image, constructing a coordinate system, and defining the first swelling information of a target patient; analyzing the thyroid postoperative image by using a skin color compensation algorithm to obtain second swelling information of the target patient; obtaining third swelling information according to the blood flow velocity of the target patient; and performing time alignment processing on all the swelling information to obtain a plurality of hematoma early warning information. According to the system, multiple imaging modes such as ultrasonic imaging and optical imaging are combined, real-time monitoring and intelligent early warning are conducted on hematoma after the thyroid surgery, the size, position and form of the hematoma can be accurately judged by fusing and analyzing multi-mode information, then hierarchical decision-making of the hematoma is achieved, accurate auxiliary diagnosis information is provided for doctors, and the diagnosis efficiency is improved. The accuracy and timeliness of thyroid postoperative hematoma monitoring are remarkably improved, complications are reduced, and the rehabilitation quality of patients is improved.

This invention relates to a method for detecting tRF-type gastric cancer molecular markers in plasma and their application in the preparation of a gastric cancer auxiliary diagnostic kit. The kit is characterized by including reagents for detecting tRF-18-79MP9P04, tRF-30-87R8WP9N1EWJ, tRF-21-V2989UV3B, and tRF-33-P4R8YP9LON4VDP in plasma samples. Compared with existing technologies, the advantages of this invention are: the kit combines tRF-18-79MP9P04, tRF-30-87R8WP9N1EWJ, tRF-21-V2989UV3B, and tRF-33-P4R8YP9LON4VDP as markers for the auxiliary diagnosis of early gastric cancer, enabling accurate absolute quantitative detection of target molecules and screening and identification of early gastric cancer.

This invention relates to the field of biomedical technology, specifically to HCBP6 monoclonal antibodies and their applications. This invention utilizes bioinformatics databases and online tools to analyze the structure of the HCBP6 protein, screening for highly immunogenic HCBP6 antigen peptides. Antibody 1 and Antibody 2 are obtained through immunization. The combination of Antibody 1 and Antibody 2 is used for the detection of HCBP6, exhibiting high sensitivity and good detection results. It has significant development and application value and long-term implications for the auxiliary diagnosis of fatty liver.

The invention relates to the technical field of medical auxiliary diagnosis, and particularly discloses an auxiliary diagnosis method for multifocal motor neuropathy and peingshan disease, which comprises the following steps: step S100: performing electromyogram detection, serological examination and muscle biopsy on an examined object to obtain electromyogram signal data, serological examination result data and muscle biopsy result data; s200, performing feature extraction on the electromyogram signal data, the serological examination result data and the muscle biopsy result data, and combining the extracted features to form a feature vector; step S300, obtaining output classification probabilities, wherein the classification probabilities correspond to the multi-focus motor neuropathy and the Pingshan disease, and excluding three categories of the multi-focus motor neuropathy and the Pingshan disease; electromyogram signals, serological examination and muscle biopsy multi-source data are fused to extract core features, a classification model is constructed by using a random forest or XGBoost algorithm, and the automation and standard unification of the whole diagnosis process are realized.

This invention discloses the application of reagents for detecting biomarker levels in the preparation of products for identifying obstructive sleep apnea. It relates to the field of biomarker technology and aims to overcome the shortcomings of existing technologies that rely on complex polysomnography (PSG) procedures, poor patient compliance, and a lack of effective molecular markers. The biomarkers used in this application consist of CD36 glycoprotein, 9-octadecenal, and protocatechuic acid 3-O-sulfate. This invention enables rapid and objective identification of obstructive sleep apnea by detecting the levels of the above biomarkers in plasma. The procedure is simple and well-accepted by patients. The combined use of multiple biomarkers can improve the accuracy and stability of the identification, making it suitable for screening or auxiliary diagnosis in medical institutions at different levels.

The application relates to the field of biological medicine, and particularly discloses application of saliva TP17, TP47 and TP15 specific antibodies in preparation of an auxiliary diagnostic product for neurosyphilis. Based on specific antibody immunoglobulin G (IgG) of Treponema pallidum in saliva, combined detection of saliva TP17 / IgG, TP47 / IgG and TP15 / IgG outputs a risk value of neurosyphilis of a subject, or a four combined Logistic regression discriminant model is constructed by combining serum TRUST titers, and the subject is stratified into a low-risk or high-risk group based on a preset judgment threshold, so that the comprehensive recognition capability for neurosyphilis is improved. The saliva is used as a detection sample, and the application has the advantages of non-invasiveness, convenience, easy popularization, repeatable collection and the like, and can be used for early screening, auxiliary diagnosis and clinical path management of neurosyphilis.

The application belongs to the field of biotechnology, and particularly relates to application of UBQLN1 protein in a cirrhosis diagnosis product, a kit and an in vitro detection method. The application comprises: using serum UBQLN1 protein as a marker, and applying the marker in preparation of a product for diagnosing or assisting in diagnosing cirrhosis; or applying the marker in preparation of a product for distinguishing cirrhosis from healthy individuals; or applying the marker in preparation of a product for evaluating progression of cirrhosis or a degree of liver fibrosis; and applying the marker in screening or evaluating a drug for preventing and / or treating cirrhosis.